11 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 11 of 11 clinical reviews.
NAFLD and MASLD are linked to higher rates of depression, anxiety, fatigue, and cognitive impairment. Learn how metabolic liver disease affects mental health and what treatments address both conditions.
A guide for caregivers and family members supporting someone with NAFLD or MASLD, covering diagnosis, treatment options including resmetirom and GLP-1 receptor agonists, lifestyle interventions, and how to find specialist care.
A step-by-step diagnostic algorithm for NAFLD/MASLD: who to screen, which tests to order, how to stage fibrosis, and when to refer for liver biopsy or specialist care.
A look at the biological mechanisms researchers believe drive NAFLD/MASLD progression, including lipid overload, mitochondrial dysfunction, the gut-liver axis, and genetic risk, with an honest account of what is established versus still under investigation.
Evidence-based monitoring schedule for NAFLD and MASLD, including lab frequency, imaging intervals, fibrosis staging, and when to refer to hepatology.
How genetic variants like PNPLA3, TM6SF2, and HSD17B13 influence NAFLD/MASLD risk, and what family history means for screening, diagnosis, and treatment decisions.
NAFLD affects roughly 38% of adults worldwide under the newer MASLD criteria. This evidence-based overview covers global prevalence data, regional variation, risk factor trends, and what the 2023 nomenclature change means for clinicians and patients.
A clinical history of NAFLD and MASLD treatment from the 1980s to today, covering lifestyle interventions, vitamin E, pioglitazone, and the first FDA-approved therapy resmetirom, with primary-source citations throughout.
Evidence-based nutrition and lifestyle interventions for metabolic-associated steatotic liver disease (MASLD/NAFLD), including dietary patterns, exercise prescriptions, and weight-loss targets backed by major clinical trials and society guidelines.
A comprehensive clinical review of racial and ethnic disparities in NAFLD / MASLD prevalence, severity, genetics, and treatment access, with primary-source citations and guidance.
A detailed breakdown of the socioeconomic burden of NAFLD/MASLD: healthcare costs, lost productivity, disability, health disparities, and what updated MASLD criteria mean for population-level projections.